Portola's andexanet alfa trial meets endpoints in second half of Phase III

23 June 2015
portola-big

Portola Pharmaceuticals (Nasdaq: PTLA) has announced that its andexanet alfa met the primary and secondary endpoints of the second part of Phase III ANNEXA-A trial.

The product is an experimental antidote to Eliquis (apixaban) from Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY), and in the study it rapidly reversed the anticoagulating effects of Eliquis, as indicated by anti-Factor Xa activity, and maintained these effects throughout the duration of the infusion.

The study comprised 31 healthy volunteers aged 50 to 75 who were treated with Eliquis twice a day for four days, then randomized to receive andexanet alfa, administered as a bolus followed by continued infusion for 120 minutes, or placebo.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical